A recent study indicates that individuals who come off popular GLP-1 drugs like Wegovy and Mounjaro can put back on reduced body mass at a significantly accelerated pace than those who stop conventional diet and exercise programs.
Published data in a leading medical journal shows that while overweight individuals frequently drop about a fifth of their total mass while on the medication, the mass is regained at an average rate of nearly a kilo each month upon discontinuation.
"Individuals using these treatments should be cognizant of the danger of rapid weight regain when the medication ends," cautioned expert Dr. Susan Jebb.
That rate of recovery suggests a return to starting weight within about a year and a half.
Analyzing Treatments
The research, which reviewed dozens of studies involving over 9,000 of patients, compared the results of GLP-1 agonists with conventional dieting.
Researchers emphasize that individuals who shed pounds through dieting usually see a slower creep back—approximately 100 grams monthly—post-intervention.
Understanding the Quick Regain
Experts propose the way of the drugs is key to understanding the amplified weight return.
These medications copy a body's own chemical called glucagon-like peptide-1, which helps regulate hunger.
"Long-term administration of the hormone levels several times higher than normal might result in the body to generate a reduced amount of its endogenous hormone, and could lessen responsiveness to its effects," noted Dr. Adam Collins, a dietetics expert.
"Discontinuation of this medication leads to appetite is no longer kept in check, making excessive eating far more likely."
An Ongoing Condition?
Medical guidelines recommend the jabs for people with obesity-related health risks, accompanied by prescribed lifestyle changes.
Professionals argue that, considering the high risk of weight regain, the treatment is often ongoing.
This view is echoed by drug manufacturers, who say that the findings "emphasize the persistent character of obesity," comparing it to managing conditions like diabetes.
User Experiences
Users who have stopped the jabs report a sudden resurgence of appetite.
"It felt as if something flipping and you become extremely hungry," said one woman.
The struggle is exacerbated if patients have not adopted permanent dietary or behavioural modifications during treatment.
Significant Use
Recent estimates indicate that millions of adults in the UK have tried these injections in the past year, with interest remaining high.
- Adoption is greater among women compared to males.
- The middle-aged age group shows the highest level of interest.
- A large proportion obtain the medications through private healthcare rather than the NHS.
Ultimately, clinicians emphasize that while these medications are powerful tools for weight loss, they are not a standalone solution and long-term success relies on integrated lifestyle support.
